Bitácora de admin

REA/EJAutopsy en las redes sociales


Revista Electrónica de la Autopsia

Equipo Editor de la Rev Electon Autopsia


SOS Aborto (24 horas)

LÍNEA 24 HORAS EN ESPAÑA: 693 632 326

Rescatadores Juan Pablo II: Desde el respeto a la mujer y la voluntad firme de querer ayudarla, recluta "personas apasionadas por ayudar a mujeres en situación de vida o muerte para sus hijos".

Leer más en: Recursos para embarazadas - Red Madre y Escuela de Rescatadores Juan Pablo II

Recopilatorio del NIC sobre distintos tipos de Cancer

There are more than 100 types of cancer. Here's a list from A to Z with links to expert-reviewed summaries:

Echa un vistazo al Tweet de @theNCI

Sobre la seguridad de la vacuna para los HPV

Quick Take: The HPV vaccine is recommended to reduce infections, but info on safety in pregnant women is limited.

Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes

Nikolai M. Scheller, Björn Pasternak, Ditte Mølgaard-Nielsen, Henrik Svanström, and Anders Hviid.

N Engl J Med 2017; 376:1223-1233 March 30, 2017DOI: 10.1056/NEJMoa1612296

Fuente: Tweet de @NEJM:


About us: We provide a web-based service for healthcare professionals to present whole slide, radiology, and clinical images in a unique and meaningful way. Current presentations, tumor boards, or transporting of medical images is cumbersome. Each path a patient takes on their journey through patient care deserves to have the highest caliber of investigation. Using PathPresenter will create a seamless environment for you to present de-identified medical images, presentations and conferences.


CDC recommends only two HPV shots for younger adolescents

Press Release

For Immediate Release: Wednesday October 19, 2016

CDC today recommended that 11- to 12-year-olds receive two doses of HPV vaccine at least six months apart rather than the previously recommended three doses to protect against cancers caused by human papillomavirus (HPV) infections. Teens and young adults who start the series later, at ages 15 through 26 years, will continue to need three doses of HPV vaccine to protect against cancer-causing HPV infection.

“Safe, effective, and long-lasting protection against HPV cancers with two visits instead of three means more Americans will be protected from cancer,” said CDC Director Tom Frieden, M.D., M.P.H. “This recommendation will make it simpler for parents to get their children protected in time.”

The Advisory Committee on Immunization Practices (ACIP) voted today to recommend a 2-dose HPV vaccine schedule for young adolescents. ACIP is a panel of experts that advises the CDC on vaccine recommendations in the United States. CDC Director Frieden approved the committee’s recommendations shortly after the vote. ACIP recommendations approved by the CDC Director become agency guidelines on the date published in the Morbidity and Mortality Weekly Report (MMWR).

CDC and ACIP made this recommendation after a thorough review of studies over several meetings. CDC and ACIP reviewed data from clinical trials showing two doses of HPV vaccine in younger adolescents (aged 9-14 years) produced an immune response similar or higher than the response in young adults (aged 16-26 years) who received three doses.

Generally, preteens receive HPV vaccine at the same time as whooping cough and meningitis vaccines. Two doses of HPV vaccine given at least six months apart at ages 11 and 12 years will provide safe, effective, and long-lasting protection against HPV cancers. Adolescents ages 13-14 are also able to receive HPV vaccination on the new 2-dose schedule.

CDC will provide guidance to parents, healthcare professionals, and insurers on the change in recommendation. On October 7, 2016, the U.S. Food and Drug Administration (FDA) approved adding a 2-dose schedule for 9-valent HPV vaccine (Gardasil® 9) for adolescents ages 9 through 14 years. CDC encourages clinicians to begin implementing the 2-dose schedule in their practice to protect their preteen patients from HPV cancers.

ACIP, CDC, FDA and partners monitor vaccines in use in the U.S. year-round. These updated recommendations are an example of using the latest available evidence to provide the best possible protection against serious diseases.

Fuente: Tweet de @CDC_Cancer

Human Papillomavirus (HPV) Vaccines

What are human papillomaviruses?
Which cancers are caused by HPV?
Who gets HPV infections?
Can HPV infections be prevented?
What HPV vaccines are available?
How do HPV vaccines work?
How effective are HPV vaccines?
Why are these vaccines important?
Why is it important for more people to be vaccinated?
How safe are the HPV vaccines?
Who should get the HPV vaccines?
Should the vaccines be given to people who are already infected with HPV?
Should women who already have cervical cell changes get the vaccines?
Do women who have been vaccinated still need to be screened for cervical cancer?
How much do these vaccines cost, and will insurance pay for it?
What research is being done on strategies to prevent HPV infection?
How can people learn more about HPV infection?

Follow the link to

Fuente: Tweet de @theNCI

Understanding Cervical Changes: A Health Guide for Women

Most women who have abnormal cervical screening tests do not have cervical cancer. Most have early cell changes that can be monitored, since they often go away on their own – or treated early, to prevent problems later. It is important to get the follow-up visits, tests, or treatment that your health care provider advises.

You can also access the information on this page as an e-book or PDF. Use this information to help you talk with your doctor after an abnormal cervical cancer screening result. If you have additional questions about cervical cancer screening, you may contact the National Cancer Institute.

Fuente: Tweet de @theNCI:

Aumento del cancer oral

Mouth cancer rates are increasing, but why?

Over the decades, our society has changed enormously – and with it our lifestyles.

And because the rates of many types of cancer are linked to things we do (or not) every day, as well as our jobs and things in our environment, cancer rates have changed too.

November is mouth cancer action month. Mouth cancers are now the tenth most common cancer in UK men, and fifteenth most common in UK women.

That’s compared to thirteenth in men, and seventeenth in women, back in 2002.

To put this in context, the rate of being diagnosed has risen by around a third over that period, increasing from nine cases per 100,000 people in 2002 to 12 cases per 100,000 in 2012.

Fuente Tweet de @CR_UK - Cancer Research UK > Cancer news > Science blog >Mouth cancer rates are increasing, but why?

The Pap Test and Bethesda 2014

The Pap Test and Bethesda 2014
“The reports of my demise have been greatly exaggerated.” (after a quotation from Mark Twain)

Nayar R., Wilbur D.C.

Abstract: The history of ‘The Bethesda System' for reporting cervical cytology goes back almost 3 decades. This terminology and the process that created it have had a profound impact on the practice of cervical cytology for laboratorians and clinicians alike. The Bethesda conferences and their ensuing output have also set the stage for standardization of terminology across multiple organ systems, including both cytology and histology, have initiated significant research in the biology and cost-effective management for human papillomavirus-associated anogenital lesions, and, finally, have fostered worldwide unification of clinical management for these lesions. Herein, we summarize the process and rationale by which updates were made to the terminology in 2014 and outline the contents of the new, third edition of the Bethesda atlas and corresponding website.

Acta Cytologica 2015;59:121-132. (

Cancer oral • Información relevante (gráfica)

Entrevista con el Cardenal Ricardo Ezzati, Mensaje

ENTREVISTA: Proyecto de despenalización aborto en tres causales / Cardenal Ricardo Ezzati, Mensaje

Current status of human papillomavirus vaccination

Current status of human papillomavirus vaccination

Brotherton, Julia M.L.; Ogilvie, Gina S.

Abstract: Purpose of review: In this article, we review the impact of the quadrivalent and bivalent prophylactic human papillomavirus (HPV) vaccines on HPV infection and disease, review alternative vaccine dosing schedules, the vaccination of men and the nine-valent HPV vaccine. Recent findings: HPV vaccines have had dramatic impacts on the prevalence of targeted HPV types (6,11,16 and 18), genital warts and precancerous cervical lesions. Population coverage would be facilitated by adopting two-dose schedules, with recent findings that two-dose schedules in young adolescents are as immunogenic as three doses in young adults. Extension of vaccination to men, particularly for men who have sex with men, could further reduce population prevalence of HPV and provide direct protection to men against genital warts and anal, penile and oropharyngeal cancers. The nine-valent HPV vaccine has demonstrated equivalent protection against the four types in the quadrivalent vaccine and high efficacy against the next five commonest causes of cervical cancer (HPV types 31,33,45,52 and 58). If cost-effective, it may extend the spectrum of protection against cervical cancer available through vaccination. Summary: HPV vaccination is an effective strategy for reducing the burden of HPV-related disease. New schedules, target populations and vaccines promise to expand this potential further.

Current Opinion in Oncology. 2015; 2(5):399–404

Recent Papillomavirus Research Articles

Recently published articles available on ScienceDirect.

Elsevier wordmark

Recent Papillomavirus Research Articles

Additional Guidance Online for Providers Regarding 9-Valent HPV Vaccine Use Among Persons Who Previously Received HPVVaccination

CDC. Centers for Disease Control and Prevention. CDC 24/7: Saving Lives. Protecting People.

Additional Guidance Online for Providers Regarding 9-Valent HPV Vaccine Use Among Persons Who Previously Received HPV Vaccination

July 31, 2015 / 64(29);806

A 9-valent human papillomavirus (HPV) vaccine (Gardasil 9, Merck and Co., Inc.) was licensed for use in females and males in the United States in December 2014. This is the third HPV vaccine licensed by the Food and Drug Administration; the other vaccines are the bivalent HPV vaccine, licensed for use in females, and the quadrivalent HPV vaccine, licensed for use in females and males.

In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent HPV vaccine as one of three HPV vaccines that can be used for routine vaccination of females and one of two HPV vaccines for routine vaccination of males. ACIP recommendations were published in a March 2015 report. Additional information has been posted on the CDC website to provide guidance on issues that were not addressed in the March report but are likely to arise during the transition to 9-valent HPV vaccine, including questions about use of 9-valent HPV vaccine among persons who previously received bivalent or quadrivalent HPV vaccine 9vHPV Guidance PDF.

Fuente: Tweet de @CDC_Cancer -